2023

Research collaboration has resulted in new ‘liquid biopsy’ research workflowusing nanopore sequencing to detect molecules that are associated with cancer,circulating in blood. Thursday 16th March Oxford Nanopore Technologies and Dutch start-up Cyclomics today announced the ‘developeraccess’ of a new research workflow that combines the world’s first nanopore sequencing-basedsolution for ultra-sensitive detection of circulating tumour DNA (ctDNA). The method works by… Read More »Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

To accelerate the development of innovate technologies in the field of cancer genetic testing, Cyclomics has completed a financing round driven by a group of private investors. In recent years, the primary focus of Cyclomics has been on the development of its core CyclomicsSeq technology, which has found its way in multiple collaborative research projects aimed at detection of genetic… Read More »Cyclomics announces completion of seed financing round